Sign In
Buy NVO
$47.42
+1.52 (+3.31%)
At Close: Jun 23, 2026
Novo Nordisk's stock rallies after drugmaker reveals deal with OpenAI
09:11am, Tuesday, 14'th Apr 2026
Novo Nordisk is working with OpenAI on a broad deal that will use artificial intelligence to more quickly develop new medications as well as help train its workforce.
Breakfast News: Novo Seeks Edge With OpenAI Deal
07:30am, Tuesday, 14'th Apr 2026
NVO pushes for AI transformation, Bloom Energy and Oracle deepen partnership, and more
Novo Nordisk Stock Rises. An OpenAI Partnership Can Help It Find the Next Ozempic.
07:27am, Tuesday, 14'th Apr 2026
Novo's OpenAI partnership will help it discover new therapies bringing them to market faster.
Is Ozempic maker stock a buy after OpenAI partnership?
06:33am, Tuesday, 14'th Apr 2026
Novo Nordisk (NYSE: NVO), the company behind the blockbuster diabetes and weight-loss drug Ozempic, has announced a strategic partnership with OpenAI.
GLP-1 giant Novo Nordisk partners with OpenAI as pharma industry's AI race accelerates
04:30am, Tuesday, 14'th Apr 2026
The Danish drugmaker becomes the latest major pharmaceutical company to embed AI across its entire drug development pipeline, from discovery to commercial...
Burney Co. Makes New $1.37 Million Investment in Novo Nordisk A/S $NVO
04:15am, Tuesday, 14'th Apr 2026
Burney Co. acquired a new stake in shares of Novo Nordisk A/S (NYSE: NVO) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commis
ACG Metals financials supported by stronger cash generation
03:52am, Tuesday, 14'th Apr 2026
ACG Metals Ltd (LSE:ACG, OTC:ACGAF) said strong margins and cash generation from its Gediktepe mine helped drive FY2025 adjusted EBITDA to US$76.3 million,...
GLP-1 giant Novo Nordisk partners with OpenAI as pharma industry's AI race accelerates
03:33am, Tuesday, 14'th Apr 2026
The Danish drugmaker becomes the latest major pharmaceutical company to embed AI across its entire drug development pipeline, from discovery to commercial operations. Novo Nordisk (NYSE:NVO), the Dani
Connecting Excellence Group receives Bitcoin payment for recruitment services in UK-listed first
03:09am, Tuesday, 14'th Apr 2026
Connecting Excellence Group Plc (AQSE:XCE, OTCQB:XCELF), the international executive recruitment firm that holds Bitcoin as a core treasury asset, has...
Novo Nordisk and OpenAI Partner to Speed Drug Discovery
02:37am, Tuesday, 14'th Apr 2026
The strategic partnership will integrate OpenAI's advanced AI capabilities throughout the drugmaker's operations, helping employees to analyze data and identify new drug candidates.
Novo Nordisk partners with OpenAI as AI drug discovery hopes mount
02:20am, Tuesday, 14'th Apr 2026
Novo Nordisk is partnering with OpenAI to "bring new and better treatment options to patients faster," the Danish drugmaker said Tuesday. "Integrating AI in our everyday work gives us the ability to
NVO Crashes 36% in 3 Months: Is This an Indication to Sell the Stock?
11:52am, Monday, 13'th Apr 2026
Novo Nordisk plunges 36% in three months as a weak 2026 outlook, rising competition and pricing pressure cloud near-term growth despite long-term pipeline promise.
Novo Nordisk: Don't Stop Purchasing The Dip
11:37am, Monday, 13'th Apr 2026
Novo Nordisk remains a compelling investment despite share price weakness, driven by robust innovation and a resilient, diversified drug pipeline. NVO delivered 10% sales growth, $5B FCF, and a 4.8% d
Is NVO Undervalued? DCF Says Worth $88
07:36am, Monday, 13'th Apr 2026
On April 13, 2026, we delve into the DCF analysis for Novo Nordisk AS (NVO), a company currently facing significant price performance challenges. Over the past
Novo Nordisk A/S - share repurchase programme
06:36am, Monday, 13'th Apr 2026
Bagsværd, Denmark, 13 April 2026 – On 4 February 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Cou
